Aug 2026· Discover Molecules· Vol 3· 0 citations· 151 references
TL;DR
The present review attempts to discuss the different stages of DN, the pathophysiological mechanisms involved in DN development and progression, and potential biomarkers and therapeutic approaches for the effective management of DN.
Abstract
Diabetic nephropathy (DN) is a diabetic complication that leads to the progressive deterioration of kidney function. Oxidative stress and inflammation play crucial roles in the pathogenesis of DN. Oral hypoglycemic agents such as sodium-glucose co-transporter 2 inhibitors, glucagon-like peptide 1 agonists, and dipeptidyl peptidase 4 inhibitors show renal protective effects and help in slowing the progression of the disease. Emerging therapeutic targets, including phosphodiesterase inhibitors, Vitamin D analogues, and others, are being explored for treating DN. The development of newer biomarkers needs more attention and clinical acceptance for the timely diagnosis and management of DN. The present review attempts to discuss the different stages of DN, the pathophysiological mechanisms involved in DN development and progression, and potential biomarkers (Neutrophil Gelatinase-Associated Lipocalin, β2-microglobulin, Kidney Injury Molecule-1, Serum homocysteine, β-trace protein, Angiotensinogen, Osteopontin, Urinary exosomes, MicroRNAs) and therapeutic approaches for the effective management of DN.
Diabetic kidney disease (DKD) is among the most common and severe microvascular complications of diabetes and represents a leading cause of end-stage renal disease (ESRD) worldwide. Currently, although strict glycemic and blood pressure control, together with the use of renin–angiotensin system inhibitors, sodium-gluco...
Xu-Hao Li, Ya-Miao Wu, Ye Shi et al.· Frontiers in Endocrinology· 0 citations
The pathophysiological mechanisms underlying DKD are summarized, the mechanistic rationale for integrating SGLT2 inhibitors with exercise is examined, and emerging experimental and clinical evidence regarding their potential effects on renal function, metabolic control, cardiovascular health, and exercise capacity is d...
Hua-Juan Li, Ming-Xian Ai, Xiang-Yu He et al.· Frontiers in Medicine· 0 citations
An overview of the key signaling pathways and molecular mediators that underlie typical pathophysiological processes in diabetic kidney disease is presented and central role of transforming growth factor-beta in activating various signaling pathways is noted.
O. A. Nagibovich, A. L. Kovalenko, O. S. Ketlinskaya· Nephrology (Saint-Petersburg...· 0 citations
Background:
Chronic kidney disease (CKD) is a global health problem, ranking as the 12
th
leading cause of disability and the 9
th
leading cause of death worldwide, affecting over 14% of adults. Among the causes is diabetic nephropathy (DN), a common microvascular complication of diabetes characterised by albumi...
L. Petrov, P. Gateva· Journal of Biomedical and Cl...· 0 citations
INTRODUCTION/OBJECTIVE
Diabetic Nephropathy (DN) remains a leading cause of end-stage renal disease worldwide, characterized by a complex interplay of oxidative stress, chronic inflammation, and circadian rhythm disruption. Despite standard-of-care treatments like RAS inhibitors and newer agents like SGLT2 inhibitors a...
Mohammad Saleh Chapani, Kosar Ostadmohammadi, Mohammad Moulaei-Arani et al.· Current Medicinal Chemistry· 0 citations
A chronic metabolic disease known as diabetes mellitus (DM) can be caused by either impaired insulin sensitivity or inadequate insulin synthesis. Elevated blood sugar levels are a symptom of this illness, which disrupts the body's normal digestion of proteins, lipids, and carbohydrates. Systemic consequences such as re...
Y. Ahire, Jayesh Patil, Obaidurraheman Mohammed Saleem et al.· Journal of Pharmaceutical Re...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.